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CD95 maintains stem cell-like and non-classical EMT
programs in primary human glioblastoma cells
M Drachsler1,9, S Kleber1,9, A Mateos1, K Volk1, N Mohr1, S Chen1, B Cirovic2, J Tüttenberg3, C Gieffers4, J Sykora4, CR Wirtz5,
W Mueller6, M Synowitz7,8 and A Martin-Villalba*,1
Glioblastoma (GBM) is one of the most aggressive types of cancer with limited therapeutic options and unfavorable prognosis.
Stemness and non-classical epithelial-to-mesenchymal transition (ncEMT) features underlie the switch from normal to neoplastic
states as well as resistance of tumor clones to current therapies. Therefore, identification of ligand/receptor systems maintaining
this privileged state is needed to devise efficient cancer therapies. In this study, we show that the expression of CD95 associates
with stemness and EMT features in GBM tumors and cells and serves as a prognostic biomarker. CD95 expression increases in
tumors and with tumor relapse as compared with non-tumor tissue. Recruitment of the activating PI3K subunit, p85, to CD95 death
domain is required for maintenance of EMT-related transcripts. A combination of the current GBM therapy, temozolomide, with a
CD95 inhibitor dramatically abrogates tumor sphere formation. This study molecularly dissects the role of CD95 in GBM cells and
contributes the rational for CD95 inhibition as a GBM therapy.
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Recent studies have identified a highly tumorigenic population
of cancer cells with stem cell-like properties, often termed
cancer stem cells (CSCs), in mouse models of a variety of
solid tumors.1–3 These studies define CSCs as a restricted
population of cells with extensive clonogenic potential that
generate more ‘differentiated’ progeny with reduced long-term
proliferative capacity. The acquisition and maintenance of a
stem cell-like state by cancer cells has been linked to the
process of epithelial-to-mesenchymal transition (EMT).4,5
Because of their intrinsic resistance to radiotherapy and
chemotherapy, CSCs can replenish a tumor after an initially
successful therapy.1,6 Thus CSCs and their microenvironment
appear as attractive therapeutic targets to eliminate the
repository potential of a tumor.
In order to design CSC-based therapies in the clinical
setting, reliable surface markers for the identification of CSCs
need to be established. In case of glioblastoma (GBM), a
plethora of such markers, including Prominin (CD133), stage-
specific embryonic antigen 1 (CD15), Integrin α6 (ITGA6),
CD44, Ephrin A2 (EphA2), Ephrin A3 (EphA3) and myeloid
elf-1-derived factor (MEF), has been proposed.7–13 However,
surface marker-negative GBM cells are also able to effectively
initiate tumor growth, and therefore, great caution is
recommended when designating a marker-positive cell as a
GBM stem cell (GSC).11,14,15
CD95 (also known as FAS or APO-1) came to the fore in
1989 as a potential therapeutic target in cancer owing to its
function as a trigger of apoptosis.16,17 Activation of CD95
leads to recruitment and activation of caspases that irrever-
sibly induce apoptosis.18 In addition, phosphorylation of
tyrosine within CD95 intracellular death domain has been
observed following binding by CD95 ligand (CD95L).19,20
Extensive characterization of the role of CD95 in cancer
has, however, revealed that malignant tumor cells are
generally resistant to CD95-induced apoptosis. Instead,
activation of CD95 in a variety of solid tumors increases
motility and invasion of tumor cells.19 In GBM, invasive
migration of tumor cells is mediated by downstream signaling
via Yes and PI3K and can be significantly reduced by inhibition
of CD95 activation.20 Indeed, CD95 is required for optimal
cancer cell growth and migration while inhibition of CD95
signaling in established epithelial tumors induces cancer cell
death.21–23 In breast cancer, CD95/CD95L signaling promotes
proliferation of a population of CSCs.24 Non-apoptotic CD95
signaling is also observed under non-malignant conditions.
In neural stem cells (NSCs), activation of CD95 increases
survival and activation for injury-induced brain repair.25
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Figure 1 CD95 is a prognostic biomarker in GBM patients and linked to stem cell and EMT gene expression patterns. (a) CD95 expression in TCGAGBM samples compared
with unmatched non-tumor control tissue (Wilcoxon test). (b) CD95 expression compared between distinct GBM subtypes in the TCGA data set (Wilcoxon test with Holm
correction). (c) Overall survival in TCGA GBM patients stratified according to CD95 expression. (d) Progression-free survival in TCGA GBM patients stratified according to
CD95 expression (log-rank test). (e) Overall survival in TCGA GBM patients grouped by subtype (log-rank test). (f) TCGA data set genes ranked according to signal-to-noise
ratios for CD95high/CD95int versus CD95low expression groups. (positive values (red): higher expression in the CD95high/int group; negative values (blue): higher expression in the
CD95low group). (g) GSEA for enrichment of an adult NSC gene signature in the ranked TCGA gene data set. (h) GSEA for enrichment of an EMT gene signature in the ranked
TCGA gene data set
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Considering these observations, we sought to elucidate
whether CD95 signalingmight also activate or maintain a stem
cell-like and EMT-programmed population of cells in GBM.
Results
CD95 is overexpressed and can serve as a prognostic
biomarker in GBM. Molecular markers have been identified
in almost every type of cancer and can aid in the estimation of
a patient’s response to treatment and prognosis.
To get insight into the role of CD95 in GBM, we analyzed a
data set accessible via The Cancer Genome Atlas (TCGA)
featuring expression as well as clinical patient data.26 When
compared with unmatched, non-tumor controls, CD95 was
found to be highly overexpressed in GBM patient samples
(Figure 1a). Based on their respective genomic and RNA
signatures, four distinct subtypes (classical, mesenchymal,
neural and proneural) have been proposed for GBM.27 When
classified according to these subtypes, CD95 was predomi-
nantly expressed in mesenchymal tumors in the TCGA GBM
data set while CD95 expression was the lowest in proneural
GBM (Figure 1b).
Correlation of tumor’s CD95 expression with clinical data
showed that CD95 might function as a prognostic molecular
marker in GBM patients. Low tumor CD95 expression was
associatedwith significantly longer overall survival (Figure 1c).
When our analysis was limited to patients in whom complete
remission of the tumor was achieved by initial therapy,
similar observations were made. Interestingly, this feature
seems to be shared by other TNF receptor family members,
as the expression levels of TNFRSF1A,B; TNFRSF11B;
TNFRSF12A and TNFRSF14 showed a similar trend toward
longer overall survival in the patients with low TNFR
expression (Supplementary Figure S1). Again, low tumor
CD95 expression was associated with a significantly
increased time to tumor recurrence after initial therapy
(Figure 1d). Of note, almost all tumors classified as low
CD95 expression GBM belonged to the proneural subtype.
Consequently, significantly longer overall survival was also
observed for patients with proneural tumors relative to other
GBM subtypes (Figure 1e and Supplementary Figure S2).
Expression of CD95 correlates with NSC and EMT gene
expression signatures. To gain deeper insight into the
processes driving the aggressive phenotype associated with
the expression of CD95, we performed gene set enrichment
analysis (GSEA).28 The genes in the TCGA data set were
ranked according to their association with high and inter-
mediate versus low CD95-expressing GBM.
At first glance, known GSC markers, including MEF,
EPHA2, ITGA6 and CD44 as well as major EMT regulators
appeared to be highly overexpressed in tumors with high or
intermediate CD95 expression (Figure 1f and Supplementary
Table S1). In contrast, DCX, ASCL1 and OLIG2, genes
normally expressed by more differentiated neuronal progeny
as well as cell cycle regulators CDKN2A and NF1, were
preferentially expressed in the less aggressive tumors
expressing low levels of CD95 (Figure 1f). GSEA showed a
significant enrichment of a NSC gene signature29 in high and
intermediate CD95-expressing tumors (Figure 1g). Similarly, a
published EMT gene signature30 was also enriched in this
group of highly aggressive GBM (Figure 1h).
CD95high GBM cells display CSC properties in vitro. To
further investigate the properties of CD95-expressing GBM
cells in vitro, tumor cells were freshly isolated from seven
surgical specimens and analyzed by flow cytometry (FACS).
A population of cells with high levels of CD95 surface
expression (CD95high) – ranging from 0.2 to 71% – was found
in each sample (Figure 2a). Co-staining for known GSC
surface markers revealed a significant enrichment of CD44,
ITGA6 and CD15 but not CD133-expressing cells within this
CD95high GBM cell population (Figures 2b–e). To test this
enrichment of known GSC markers in a larger patient cohort,
we again turned to the TCGA GBM patient data set.
Paralleling our findings in primary GBM cells, a significant
correlation was observed between the expression of CD95
and the known GSC markers CD44, ITGA6, MEF, EPHA2
and EPHA3 but not for CD133 in this data set (Figures 2f–k).
Because of the large number of patients (n=519), all
correlations were statistically significant. Nevertheless, cor-
relation was strongest between the expression of CD95 and
CD44 as well as MEF (Figures 2f and h).
These observations suggested that the CD95high GBM cell
population might possibly hold certain stem cell-like traits. We
therefore tested the self-renewal capacity of FACS-sorted
cells isolated from five patient samples by measuring sphere
formation. CD95high cells showed extensive sphere-formation
capacities, while sphere formation in CD95neg cells was very
limited (Figures 3a–e). The same was also true when the cells
were plated under limiting-dilution conditions (Figures 3f–i).
Even under highly restrictive conditions down to one cell per
well, CD95high GBM cells showed profound sphere-formation
capacities. The estimated stem cell frequencies ranged from
1 : 1 to 1 : 163 for CD95high compared with 1 : 110 to 1 : 773 for
CD95neg GBM cells (Figures 3g–i).
CD95high GBM cells are highly tumorigenic in vivo. In
order to further investigate these observed properties of
CD95high cells in vivo, primary cells were isolated from a
human sample, depleted of CD45-positive immune cells as
well as CD31-positive endothelial cells and sorted for CD95
expression. One thousand unsorted, CD95high or CD95neg
primary cells were injected into the striatum of SCID beige
mice (Figure 3j). The CD95high fraction amounted to 3.33%
while CD95neg cells made up 52.4% of cells in the patient
sample (Supplementary Figure S3). Tumor incidence was 86
and 55% for CD95high and CD95neg xenografts, respectively.
Sixteen weeks after xenotransplantation, first lesions were
detected in T2-weighted magnetic resonance imaging (MRI)
sequences (Figure 3k). From then on, the CD95high-expres-
sing tumors showed sustained growth throughout the
observation period of a further 7 weeks (Figure 3k). In
contrast, despite being able to initiate a tumor, CD95neg and
unsorted tumor cells were not able to sustain tumor growth.
After an initial growth phase of the detectable lesions, the size
of the lesion stagnated or even decreased (Figure 3k). At the
end of the MRI observation period 22 weeks after implanta-
tion, CD95high GBM cells had given rise to significantly larger
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tumors than CD95neg or unsorted cells (Figure 3l and
Supplementary Movies SM1 and SM2). The MRI-measured
tumor volumes were confirmed by histopathological analysis
in samples of tumor-bearing brains (Supplementary
Figure S3). Paralleling the significantly larger tumor in the
CD95high-injected group, those animals also showed a higher
mortality (Figure 3m).
To confirm these results, orthotopic xenotransplantation
was repeated with cells derived from a second, independent
patient sample. Because of the limited availability of primary
patient material, tumor cells were expanded by two rounds of
subcutaneous xenografting (Supplementary Figure S3).
Despite the increasingly efficient tumor formation by CD95neg
cells, CD95high cells once more sustained superior tumor
growth (Supplementary Figure S3).
Inhibition of CD95/CD95L signaling precludes sphere
formation while CD95 and CD95L are upregulated by
conventional therapy. Next we asked whether self-renewal
of GBM cells might be dependent on a CD95/CD95L signal.
We therefore treated freshly isolated GBM cells with APG101
(Apocept), a CD95-Fc fusion protein designed to scavenge
CD95L and thereby block CD95 activity. In addition, cells
were treated with the GBM standard chemotherapy,
temozolomide (TMZ) or a combination of APG101 and
TMZ. APG101 was able to significantly reduce GBM sphere
formation in combination with TMZ but not alone (Figures 4a–
c). As the inhibitor effect of APG101 is based on its binding to
CD95L, we reasoned that expression of CD95L by GBM cells
under culture conditions might be low and increased by TMZ
treatment. To test this hypothesis, we measured CD95L by
ELISA in the supernatant and lysates of GBM cells treated
with TMZ or left untreated. In two out of the four samples
tested, TMZ treatment resulted in an increase in CD95L
expression while a similar trend was observed in the
remaining samples. This could explain the inhibitory self-
renewal effect by the combination of TMZ and APG101
(Figures 4d–k).
To compare these in vitro findings to the clinical setting,
protein expression of CD95 and CD95L was examined in
tissue sections from 27 original and matched relapse tumors
(Figure 5a and Supplementary Table S2). For quantification
purposes, the different tumors were scored on a scale ranging
from two (lowest) to six (highest) according to the intensity and
area of CD95 and CD95L immunohistochemical staining
across the different tumor sections. After initial treatment,
CD95 expression was significantly upregulated in relapse
tumors (Figures 5b and c). These results point toward the
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Figure 2 CD95high GBM cells co-express known GSC markers. (a) CD95 expression in seven patient tumor samples analyzed by flow cytometry. (b–e) Co-expression of
known GSC markers CD44 (n= 7), Integrin α6 (ITGA6; n= 7), CD15 (n= 3) and CD133 (n= 7) within the patient samples (Friedman test). (f–k) Correlation of CD95 expression
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occurrence of a selection process favoring CD95-expressing
cells with increased chemoresistance. In accordance with our
findings in vitro, expression of CD95L was also upregulated in
relapsing GBM after initial treatment of the original tumor
(Figures 5d and e).
Tyrosine phosphorylation of CD95 recruits P85 and SFK
and is essential for maintenance of an EMT program in
GBM cells. We have previously suggested that phosphor-
ylation of a tyrosine residue lying within CD95’s intracellular
death domain underlies non-apoptotic downstream signals.
This hypothesis was, however, based on in silico prediction
but never demonstrated at the molecular level. To study
tyrosine phosphorylation in GBM, we transduced CD95-
negative (CD95neg) cells with lentiviral vectors entailing either
a CD95 wild type (CD95-WT) or a CD95 tyrosine-to-alanine
mutant (CD95-mut) that precludes phosphorylation. To detect
tyrosine phosphorylation of CD95 in situ, we used a proximity
ligation assay (PLA) that uses antibody–DNA conjugates to
enable the conversion of protein–protein interactions
(o40 nm distance) into detectable DNA molecules. Thus a
phosphorylated tyrosine in CD95 can be detected by the
proximity of anti-CD95 to anti-phospho-tyrosine antibodies in
GBM cells. Indeed, this assay revealed the presence of
tyrosine phosphorylation of CD95 (Figure 6a). Upon stimula-
tion with CD95L-T4, CD95 tyrosine phosphorylation strongly
increased in CD95-WT but not in CD95-mut cells (Figures 6a
and b). After establishing this cellular model, we next wanted
to test the recruitment of known downstream mediators of
non-apoptotic CD95 signals. Association of the regulatory
PI3K subunit, p85, as well as a Src-familiy-kinase member
(Sfk) with CD95 was readily detected by CD95 and phospho-
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Figure 3 CD95high GBM cells display superior self-renewal in vitro and are highly tumorigenic in vivo. (a–e) Sphere formation by FACS-sorted CD95high and CD95neg cells
freshly isolated from five patient tumor samples plated at 500 cells per well (t-test). (f) Representative gating strategy for cell sorting. (g–i) Sphere formation by CD95high and
CD95neg cells freshly isolated from three tumor samples plated under limiting-dilution conditions. Estimated stem cell frequencies: (L) CD95neg: 1 : 110, CD95high: 1 : 1 (limiting
dilution not reached); (M) CD95neg: 1 : 771, CD95high: 1 : 163; (N) CD95neg: 1 : 122, CD95high: 1 : 30. (j) 1 × 103 unsorted, CD95neg or CD95high cells were injected into the
striatum of Fox Chase SCID beige mice (n= 5 for unsorted and CD95neg, n= 6 for CD95high). (k) Tumor growth was monitored by T2-weighted MRI. (l) Tumor volumes at the end
of the MRI observation period 22 weeks after injection (ANOVA). (m) Kaplan–Meier curve showing the survival of the animals after the MRI observation period. In accordance with
the observed tumor growth, CD95high-injected animals show the highest mortality
CD95 maintains stem cell-like tumor cells in GBM
M Drachsler et al
5
Cell Death and Disease
tyrosine immunoprecipitation (IP) in naive, unsorted GBM cells
treated with CD95L (Figure 6c and Supplementary Figure S4).
Upon stimulation in lentivirally transduced GBM cells, recruit-
ment of P85 and Sfk was observed in CD95-WT but not in
CD95-mut cells (Figures 6d and e). We thus conclude that,
upon stimulation, tyrosine phosphorylation within the intracel-
lular death domain might contribute to the assembly of the
non-apoptotic CD95 signalosome in GBM cells.
We hypothesized that CD95 signaling, via tyrosine phos-
phorylation and recruitment of downstream mediators, might
induce an EMT signal that can promote stemness and invasive
migration in GBM cells. Fitting this hypothesis, expression of
CD95 correlated with the expression of the known EMT
marker genes VIM, FN1, SNAI2 andS100A4 in the TCGAdata
set (Supplementary Figure S3). To further investigate this
potential link, we measured the expression of 62 EMT-
associated genes in qPCR arrays for CD95high versus
CD95neg GBM cells sorted from 4 individual patient samples
as well as in our CD95-WT versus CD95-mut cells. Here EMT-
associated genes were again upregulated in CD95high cells
(Figure 6f and Supplementary Table S4). Furthermore, the
EMT-associated geneswere strongly downregulated in CD95-
mut cells lacking tyrosine phosphorylation within the death
domain of CD95 (Figure 6f).
Discussion
An aggressive population of GBM cells with stem cell-
like properties expresses high levels of CD95. Our results
demonstrate that CD95 can be used for isolation of a highly
aggressive population of GBM cells with certain stem cell-like
features. CD95high GBM cells exhibit superior self-renewal
capacity in vitro and are enriched in relapsing tumors after
conventional therapy. Blocking of CD95 signaling inhibits
GBM cell self-renewal. In accordance with findings in adult
NSCs as well as breast CSCs, CD95 thus seems to mediate
an activation signal in CD95high GBM cells too.24,25
Examination of the TCGA data set revealed that CD95 was
predominantly expressed in mesenchymal GBM subtype.
Studies employing genetically engineered mouse models have
shown that occurrence of genetic alterations in a certain cell
type induces formation of distinct GBM subtype tumors.31,32
In this study, the mesenchymal subtype arose from
introducing mutations in differentiated neural cells. Thus an
ongoing dedifferentiation process that confers a NSC- or
progenitor cell-like phenotype was speculated as underlying
tumor-initiation mechanism.31 Our results indicate that CD95
might be actively involved in this process by functioning as an
EMT signal. In addition, inflammatory infiltrates are highly
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(control), APG101 (APG), TMZ or a combination of both (n≥ 12 per conditions, overall comparison: one-way ANOVA, pairwise comparison: Tukey’s multiple comparison test).
(d–k) CD95L-ELISA for patient-derived cell culture supernatants (d–g) or lysates (h–k) treated with DMSO (Co) or TMZ (two sided t-test with Holm correction)
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Figure 5 Expression of CD95 and CD95L is increasing in recurrent GBM. (a) Anti-CD95 and -CD95L immunohistochemistry (IHC) of primary and matching relapsing tumors
(representative images, scale bar: 200 μm). (b) Scoring results for anti-CD95 IHC of 27 primary and relapsing tumors. (Wilcoxon test). (c) Individual relative CD95 scores (relapse
score – primary tumor score) for the 27 patients showing an overall increase of CD95 expression in the relapsing tumors (average relative score= 0.70, 95% Cl: 0.14–1.27).
(d) Scoring results for anti-CD95L IHC of 27 primary and relapsing tumors. (Wilcoxon test). (e) Individual relative CD95L scores for 27 patients showing an overall increase in
CD95L expression in the relapsing tumors (average relative score= 0.73, 95% CI: 0.13–1.33)
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Figure 6 Tyrosine phosphorylation of CD95 recruits P85 and SFK and induces ncEMT. (a) PLA for tyrosine phosphorylation of the CD95 receptor in patient-derived CD95neg
GBM cells transduced with a CD95 wild-type (CD95-WT) or CD95mutant (tyrosine-to-alanine, CD95-mut) lentivirus stimulated with PBS (Co) or CD95L-T4. (b and c) Quantification of
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prevalent within mesenchymal GBM.27 As reported previously,
innate immune cells rely on the CD95/CD95L system to be
recruited to the central nervous system after injury.33 And
lately, innate immunity has been linked to efficient reprogram-
ming in the induction of pluripotency.34 It is thus possible that a
signal mediated by CD95L-bearing immune cells can con-
tribute to the establishment of an aggressive tumor phenotype.
Additionally, we showed that expression of CD95L increases
during tumor progression and after chemotherapy. This
suggests that GBM cells themselves might be able to maintain
CD95 activity as a stimulating signal, especially later on during
disease progression.
CD95, stemness and the EMT program. As a cell of tumor
origin does not necessarily have to be a CSC, it is reasonable
to assume that there must be a way for cancer cells to acquire
stem cell traits.35 To this end, the developmental program of
EMT has been reported to confer pro-invasive as well as
stem cell-like properties to cancer cells.4,36 Similarly, the
EMT-mediating transcription factor Twist1 has been shown to
be crucial to melanoma initiation and progression.37
Our observations indicate an ongoing process similar to
EMT that maintains a population of aggressive, stem cell-like
cells in GBM. Given the fact that this process is similar but not
identical to the EMT process resulting in metastasis formation
in carcinomas, it is appropriate to denote this process as non-
classical EMT (ncEMT). CD95, via tyrosine phosphorylation of
its intracellular death domain and subsequent downstream via
the PI3K pathway, seems to be actively involved in this
process. In line with these observations, the PI3K signaling
pathway is involved in the induction of an EMT state in other
tumors as well.38 CD95 belongs to the tumor necrosis factor
alpha (TNFα) superfamily, and similarly, TNFα has been
implicated in EMT, tumorigenesis and tumor cell invasion
in various ways.39 Furthermore, inhibition of the major
EMT-regulator TGF-β has been shown to inhibit CSC activity in
GBM.7 Cells at the invasive front of GBM as well as other solid
tumors usually acquire mesenchymal traits to promote their
invasive migration.20,40,41 Another interesting aspect regard-
ing the role of EMT in cancer has been highlighted recently.
Studies in pancreatic and lung cancer have indicated that EMT
might not be the main driver of metastatic growth but might
rather induce a chemoresistant state in tumor cells.42,43
Taken together, our findings suggest an active role of CD95
in GBM growth and progression. Beyond a function as a sheer
surface marker, non-apoptotic signals mediated via phosphor-
ylation within the intracellular death domain seem to regulate
ncEMT in a manner similar to other TNFα family and tyrosine
kinase receptors. However, additional efforts are required to
further elucidate on the exact signaling pathway and its
regulation.
Implications for GBM therapy. Our results imply possible
clinical applications of CD95 as a prognostic biomarker as
well as a therapeutic target in GBM therapy. We identified low
CD95 expression as a positive prognostic biomarker predict-
ing favorable overall and recurrence-free survival.
In 2008, we discovered that CD95 induces invasive
migration of GBM.20 Based on this findings, APG101
(Apocept), a CD95-Fc fusion protein that neutralizes CD95L,
has been developed. In a first safety trial, APG101 showed no
toxicity.44 Recently, the combination of APG101 and radio-
therapy versus radiotherapy only in patients with relapsing
GBM was tested in a Phase II clinical trial.45 Surpassing all
expectations, application of the compound in combination
with radiotherapy almost doubled the progression-free survi-
val in these patients for whom only very limited therapeutic
options are available.45 Increased overall survival was also
observed upon APG101 treatment within a group of patients
featuring low levels of DNA methylation within the CD95L
promoter (and therefore expressing high levels of CD95L).
Consequently, CD95L promoter methylation status was
suggested as a biomarker to predict a tumor's response to
APG101 treatment.45
Our current study provides additional insight into possible
cellular effects of APG101. Given its supposed involvement in
the regulation of ncEMT in GBM cells, CD95 might be able to
specifically target the aggressive subpopulation of tumor cells
that we have described here. Therefore, APG101 might be a
valuable addition to conventional therapies targeting the tumor
bulk and we are eager to see its effect in the larger-scale
clinical trials to come.
Materials and Methods
TCGA data analysis. TCGA data was downloaded from the TCGA Data
Portal (https://tcga-data.nci.nih.gov/), and level-3 data from the Affymetrix U133a
microarray platform (Santa Clara, CA, USA) was used for gene expression analysis.
Subtype annotation in the TCGA data set. Samples were annotated
to the four subtypes (neural, proneural, mesenchymal and classical) defined
by Verhaak et al.,27 using a supervised approach based on support vector
machines (SVM).
A SVM model was trained with the 171 annotated samples and the 840 genes
from the signatures published by Verhaak et al.27 using the svm() function from the
R (http://cran.r-project.org) package e1071, with a radial kernel and default
parameters.27 The predictive capacity of the adjusted model was estimated by
10-fold cross-validation on the training set, reaching a 91.23% total accuracy. The
trained model was then used to predict the subtype of the 376 non-annotated tumor
samples in the TCGA data set. These new annotated samples were added to the
initial 171, adding up to 547 samples belonging to 528 patients. When there were
multiple samples for a patient, the prediction was always consistent.
Gene set enrichment analysis. GSEA was performed as described by
Subramanian et al.28 NSC and ncEMT signatures were derived from the published
data.29,30
Handling of patient tumors and tumorsphere cultures. Collection
of patient samples was approved by the Ethics committee of the Charité University
Medicine, Campus Virchow-Klinikum, Berlin (EA3/023/06) and the Medical Ethics
committee II of the medical faculty Mannheim of the University of Heidelberg
(EA2/101/08). All specimens were examined by a neuropathologist to confirm that
each tumor met the WHO criteria for GBM. Samples were cut in small pieces,
digested using Dispase, DNAse and Papain and cultured in neurobasal medium
(see Supplementary Information) in an incubator at 37 °C and 5% CO2.
Complete neurobasal medium for tumorsphere cultures. Neuro-
basal medium (Invitrogen, Thermo Fisher Scientific GmbH, Schwerte, Germany)
supplemented with B27 (Invitrogen), Glutamax (Invitrogen), Heparin (2 μg/ml)
(Sigma-Aldrich Chemie GmbH, Taufkirchen, Germany) and the growth factors EGF
(20 ng/ml; PromoCell, Heidelberg, Germany) and bFGF (20 ng/ml; Provitro, GmbH,
Berlin, Germany) were used.
Flow cytometry. For FACS analysis, all washing and staining steps were
performed in phosphate-buffered saline containing 5% of fetal calf serum. Cells
were incubated with the respective antibodies (see ‘Antibodies’ section) for 1 h on
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ice in the dark. Appropriate single-stained and isotype controls were performed. All
antibodies were used at the dilution recommended by the manufacturer or if not
given otherwise 1 μg per 100 μl of sample volume. For exclusion of death cells,
samples were stained with Hoechst 33342 (Invitrogen). For compensation,
CompBeads (Beckton Dickinson, Heidelberg, Germany) were used according to
the manufacturer's recommendations. Measurements were performed at a FACS
Canto II (405 nm-488 nm-633 nm laser setup, Beckton Dickinson) using the FACS
Diva software (Beckton Dickinson). At least 10 000 events were recorded. Results
were analyzed using FlowJo (Tree Star, Ashland, Orlando, USA).
For FACS sorting, all washing and staining steps were performed in phosphate-
buffered saline containing 2% B27 serum-free supplement (Gibco, Thermo Fisher
Scientific GmbH, Schwerte, Germany) and 1% of human IgG (Gammunex, Talecris
Biotherapeutics, Commons Research Triangle Park, NC, USA) under sterile
conditions. Co-staining with anti-CD45-APC-Cy7 (eBioscience, Inc./Affymetrix,
San Diego, CA, USA) (20 μl/test) was performed to exclude myeloid cells. To
exclude dead cells, the samples were stained with propidium iodide (BD Bioscience,
Heidelberg, Germany). Sorting was performed on FACSAria II/III (BD Bioscience) at
the Flow Cytometry Core Facility of the German Cancer Research Center (DKFZ).
Tumorsphere assays, limiting-dilution assays (LDA) and treat-
ment. Five hundred cells per well (or down to one cell per well for limiting dilution)
were plated in complete neurobasal medium, and sphere formation was measured
after 10 days. For LDAs, stem cell frequencies were calculated in R using the limdil
function in the statmod package. In the treatment experiments, TMZ (10 μM) and
APG101 (10 μg/ml) were added to the culture medium.
CD95L-ELISA. GBM cells were treated with DMSO (Co) or with Temodal (TMZ,
100 μM) for 24 h, 4 days and 7 days. Supernatants and cell lysates were collected
and analyzed by CD95L-ELISA (R&D, Cat. No. DFL00, Minneapolis, MN, USA)
following the manufacturer's protocol.
Scoring of immunostained paraffin sections. Consecutive sections of
formalin-fixed paraffin-embedded primary GBMs and corresponding recidives from
a total of 27 patients were stained against CD95 and CD95L. Stained sections were
scored 1–3 for positive area (1: positive o1/3; 2: 1/3≤ positive≤ 2/3; 3: positive
42/3) and intensity (1: weak; 2: medium; 3: strong). Combined scores for area and
intensity of CD95 and CD95L were calculated by addition of the area and intensity
scores. Relative scores for CD95 and CD95L were calculated by subtraction of the
combined score of the recidive tumors from the combined score of the primary
tumors.
Proximity ligation assay. Duolink reagents (Sigma, Cat. Nos. DUO92101-
1KT, DUO92009-1KT and DUO92010-1KT) were used following a slightly modified
protocol. In brief, 1 × 106 GBM cells (T6 CD95-WT and T6 CD95-mut) were treated
with CD95L-T4 (40 ng/ml) for 10 min at 37 °C or left untreated as a control (Co).
Cells were collected and fixed with 2% PFA for 10 min at RT. After washing with
PBS, the cells were permeabilized with 0.5% Triton/PBS for 15 min at RT. Cells
were incubated for 72 h with the respective primary antibodies (see ‘Antibodies’
section) diluted in 0.5% Triton plus 2% B27 in PBS. After washing, the procedure
was followed as described in the manufacturer's protocol.
Immunoprecipitation. Cells (1 × 107) were treated with 40 ng/ml CD95L-T4
for 5, 10 and 15 min (or left untreated as control) at 37 °C. After washing twice with
PBS plus phosphatase inhibitors (NaF, NaN3, pNPP, NaPPi, β-Glycerolphosphate,
10 mM each and 1 mM orthovanadate), cells were lysed in IP Lysis Buffer (20 mM
Tris/HCl, pH 7.5, 150 mM NaCl, 2 mM EDTA, 1 mM phenylmethylsulfonyl fluoride,
protease inhibitor cocktail (Roche), 1% Triton X-100, 10% glycerol, and
phosphatase inhibitors (NaF, NaN3, pNPP, NaPPi, ß-Glycerolphosphate, 10 mM
each and 1 mM orthovanadate). Protein concentration was determined using a BCA
Kit (Pierce, Thermo Fisher Scientific GmbH, Schwerte, Germany), and 500 μg of
protein was used as input. IP of CD95 or phospho-tyrosine was performed overnight
with either an anti-CD95- (Apo-1, Apogenix, Heidelberg, Germany) or an anti-
phospho-tyrosine biotinylated (Millipore/Merck Chemicals GmbH, Darmstadt,
Germany) antibodies and 40 μl protein-A Sepharose Beads and the corresponding
isotype control.
Beads were washed five times with 20 volumes of lysis buffer, mixed with 40 μl of
2 × Laemmli buffer and analyzed on 10% SDS-PAGE. Afterwards, proteins were
transferred onto nitrocellulose membranes by semi-dry turbo-blotting. The non-
specific binding sites on the nitrocellulose membrane were blocked by incubation with
5% skim-milk powder in PBS/Tween for 1 h. Later, the primary antibodies (anti-P85,
Millipore; anti-SFK, Cell Signaling Technology Europe (B.V./New England Biolabs, ZA
Leiden, The Netherlands); anti-CD95, Cell Signaling and anti-phospho-tyrosine,
Millipore) diluted in 5% skim milk powder in PBS/Tween were incubated at 4 °C
overnight. After washing again, the membranes were incubated for 1 h with the
corresponding secondary antibody conjugated with horseradish peroxidase (HRP).
The HRP signal was visualized by incubation with ECL solution and exposure to X-ray
films (Hyperfilm, Amersham, Freiburg, Germany).
RNA isolation. RNA isolation was performed using the mirVana Kit (Ambion,
Thermo Fisher Scientific GmbH, Schwerte, Germany) following the manufacturer's
total RNA purification protocol.
EMT-qPCR array. RNA from sorted tumor samples was converted into cDNA
using the SuperScript VILO cDNA Synthesis Kit (Life Technologies, Thermo Fisher
Scientific GmbH, Schwerte, Germany) following the manufacturer's protocol.
Later, cDNA was mixed with RT2 SYBR Green qPCR Mastermix (SABioscience-
Germany — QIAGEN GmbH, Hilden, Germany Cat. No. 330522) and loaded on
either 96-well or 384-well RT2 Profiler Epithelial to Mesenchymal Transition PCR
Array plates (Qiagen, GmbH, Hilden, Germany Cat. No. PAHS-090Z; PAHS-090ZE-4).
The arrays were run as technical triplicates either on an ABI 7500 Real-Time PCR-
System (Applied Bioscience/Thermo Fisher Scientific GmbH, Schwerte, Germany)
for the 96-well plates or an CFX384 Real-Time PCR-System (Bio-Rad Laboratories
GmbH, München, Germany) following the manufacturers' protocols, and the results
for individual samples were averaged between the triplicates. Primary analysis was
performed using an Excel sheet (Qiagen GmbH) provided by the manufacturer, and
gene expression was normalized to ACTB expression.
Expectations regarding an upregulation or downregulation in EMTwere annotated
by the manufacturer's guidelines for some of the genes in the array and was
complemented by information derived from searching Pubmed for non-
annotated genes.
Generation of heat maps. To present the EMT-qRT-PCR Array data from
four different patient samples as well as GBM cells lentiviral induced with CD95-WT
or a CD95 tyrosine-to-alanine mutant (CD95-mut), a heat map for each gene known
to be upregulated during EMTwas generated. The heat map represents the log10 of
the ratio between the ACTB normalized expression of CD95high and CD95neg or
CD95WT and CD95nut sorted cells from each tumor sample.
Antibodies. The following antibodies were used for flow cytometric stainings:
Anti-human CD95 (APO1, Apogenix), labeled with LightningLink APC-Cy7 (Innova
Biosciences Ltd., Cambridge, UK); Mouse IgG Isotype Control (Sigma Aldrich),
labeled with LightningLink APC-Cy7; Anti-human APG101 (Apogenix), labeled with
LightningLink APC (Innova); Rabbit IgG XP Isotype Control (Cell Signaling), labeled
with LightningLink APC (Innova); Anti-human CD44 PE-Cy7 (eBioscience); Rat
IgG2b K Isotype Control PE-Cy7 (eBioscience); Anti-human CD15 PerCP
(BioLegend); Mouse IgG1 K Isotype Control PerCP (BioLegend, San Diego, CA,
USA); Anti-human CD133 PE (Miltenyi Biotec GmbH, Bergisch Gladbach,
Germany); and Mouse IgG1 Isotype Control PE (Miltenyi).
The following antibodies were used for immunohistochemistry on paraffin-
embedded tissue: Anti-human CD95 (Apogenix), anti-human CD95L (G24BD),
biotinylated anti-mouse and anti-rabbit secondary antibodies, and anti-streptavidine-
alkaline phosphatase.
The following antibodies were used for PLA: Anti-human CD95 (EnzoLife
Sciences, Bergisch Gladbach, Germany; Enzo Life Sciences GmbH, Lörrach,
Germany) and anti-phospho-Tyrosine biotinylated (Millipore).
The following antibodies were used for IP and immune blotting: anti-human CD95
(APO-1, Apogenix), labeled with LightningLink Biotin (Innova), anti-phospho-Tyrosine
biotinylated (Millipore), anti-human P85 (Millipore), Sfk (New England Biolabs/Cell
Signaling Technology), anti-human CD95 (Fas4C3, BioLegend), anti-mouse HRP,
and anti-rabbit HRP (Dianova Gmb, Hamburg, Germany).
General statistics. Sample names, group sizes and statistical tests are
indicated in the respective figure/figure legends. P-values: *P≤ 0.05, **P≤ 0.01,
***P≤ 0.001. Data are presented as mean± S.E.M. Box whisker charts display
minimum to maximum values (whiskers) and 25% and 75% percentiles (box). If not
stated otherwise, data visualization and analysis was performed with GraphPad
Prism 6 (GraphPad Software Inc., La Jolla, CA, USA).
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